ADC
Agree Realty Corporation
$75.46
-0.22
(-0.29%)
Mkt Cap
9.06B
Volume
630,945
52W Range
69.56-82.08
Sector
Real Estate
Beta
0.50
EPS (TTM)
1.86
P/E Ratio
40.57
Revenue (TTM)
750.04M
Rev Growth (5Y)
+23.7%
EPS Growth (5Y)
+0.1%
AlphaVal · Fair Value
$66.55
Overvalued · Mild
13.4% above fair value
AlphaQuality · Grade
B-
Real Estate Investment Trust
63.7 / 100 composite
Company Description
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 718.40M | 617.10M | 537.50M | 429.81M | 339.32M | 248.57M | 187.48M | 137.12M | 111.52M | 91.53M | 69.97M | 53.56M |
| Net Income | 204.35M | 189.20M | 169.96M | 152.44M | 122.27M | 91.38M | 80.08M | 58.17M | 58.11M | 45.12M | 39.02M | 18.49M |
| EPS | 1.77 | 1.79 | 1.70 | 1.84 | 1.79 | 1.76 | 1.96 | 1.81 | 2.09 | 1.97 | 2.17 | 1.24 |
| Free Cash Flow | 504.14M | 431.97M | 391.60M | 362.12M | 246.31M | 142.96M | 126.71M | 93.25M | 82.20M | 61.73M | N/A | N/A |
| FCF / Share | 4.55 | 4.27 | 4.11 | 4.60 | 3.69 | 2.76 | 3.12 | 2.91 | 2.98 | 2.70 | N/A | N/A |
| Operating CF | 504.14M | 431.97M | 391.60M | 362.12M | 246.31M | 142.96M | 126.71M | 93.25M | 82.20M | 61.73M | N/A | N/A |
| Total Assets | 9.80B | 8.49B | 7.77B | 6.71B | 5.23B | 3.89B | 2.66B | 2.03B | 1.49B | 1.11B | N/A | N/A |
| Total Debt | 3.35B | 2.83B | 2.45B | 1.98B | 1.88B | 1.31B | 961.30M | 720.41M | 519.56M | 400.92M | N/A | N/A |
| Cash & Equiv | 16.30M | 6.40M | 10.91M | 27.76M | 43.25M | 6.14M | 15.60M | 53.95M | 50.81M | 33.40M | N/A | N/A |
| Book Value | 6.27B | 5.51B | 5.20B | 4.63B | 3.42B | 2.52B | 1.69B | 1.24B | 908.66M | 682.98M | N/A | N/A |
| Return on Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 | 0.07 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.81M | 190.49M | 183.22M | 175.53M | 169.16M | 160.73M | 154.33M | 152.57M | 149.45M | 144.16M | 136.81M | 129.90M |
| Net Income | 62.23M | 56.04M | 52.12M | 49.20M | 47.00M | 45.24M | 44.38M | 54.72M | 44.86M | 45.95M | 41.52M | 40.87M |
| EPS | 0.50 | 0.47 | 0.45 | 0.44 | 0.42 | 0.42 | 0.42 | 0.53 | 0.43 | 0.44 | 0.41 | 0.42 |
| Free Cash Flow | (267.18M) | 111.31M | 146.52M | 119.64M | 126.66M | 91.40M | 128.61M | 112.81M | 99.15M | 98.01M | 109.86M | 89.56M |
| FCF / Share | -2.23 | 0.97 | 1.32 | 1.12 | 1.18 | 0.88 | 1.28 | 1.12 | 0.99 | 0.98 | 1.13 | 0.96 |
| Operating CF | 145.16M | 111.31M | 146.52M | 119.64M | 126.66M | 91.40M | 128.61M | 112.81M | 99.15M | 98.01M | 109.86M | 89.56M |
| Total Assets | 10.18B | 9.80B | 9.48B | 9.08B | 8.80B | 8.49B | 8.18B | 8.00B | 7.87B | 7.77B | 7.65B | 7.27B |
| Total Debt | 3.29B | 3.35B | 3.42B | 3.27B | 3.00B | 2.83B | 2.72B | 2.71B | 2.55B | 2.45B | 2.23B | 2.14B |
| Cash & Equiv | 25.08M | 16.30M | 13.70M | 5.82M | 7.92M | 6.40M | 13.24M | 9.64M | 6.31M | 10.91M | 6.38M | 8.07M |
| Book Value | 6.24B | 6.27B | 5.87B | 5.65B | 5.64B | 5.51B | 5.29B | 5.16B | 5.18B | 5.20B | 5.24B | 4.98B |
| Return on Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
ADC News
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
Agree Realty Declares Monthly Common and Preferred Dividends
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program